Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2015

Open Access 01-07-2015 | Short Communication

Comparison of saliva interleukin-2 concentration to the condition of gums in children with acute lymphoblastic leukaemia during anti-tumour treatment

Author: Elżbieta Pels

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2015

Login to get access

Abstract

Purpose

Subjects undergoing chemotherapy often develop disorders in salivation and changes in salivary composition. Therefore, a tendency to inflammatory states developing within oral mucosa is often observed. The objective of the study was to assess the effect of disturbed immunity on the gum condition in children with acute lymphoblastic leukaemia (ALL) during anti-tumour treatment and to compare saliva interleukin-2 (IL-2) concentration in relation to the condition of gums oral mucositis—must be removed in children with ALL.

Methods

The study included 78 children with ALL in followed three examinations and a control group included 78 healthy children. Dental examination of the children with ALL and the control group included the evaluation of gingival condition by gingival index (GI). Children’s unstimulated saliva samples were taken, and IL-2 concentration was determined by Human IL-2 EIA.

Results

Mean GI higher than 1 was observed in 3.17 % children with ALL. The results found higher frequency of gingival inflammations in children with ALL on chemotherapy compared with the healthy controls. A comparison of results for a given patient during anti-tumour therapy with regard to salivary IL-2 showed significant differences between examination 2 and examination 3. The results indicated that IL-2 level in saliva was twice higher in a patient during chemotherapy.

Conclusions

An increase in salivary level of the proinflammatory IL-2 cytokine in ALL children during chemotherapy may cause pathological changes in the condition of the gums. An increase in salivary IL-2 level most probably results from a micro-injury of oral mucosa following administration of cytostatics, which in turn may cause oral mucositis in children with ALL.
Literature
1.
Thomaz EB, Mouchrek JC Jr, Silva AQ, Guerra RN, Libério SA, da Cruz MC, Pereira AL (2013) Longitudinal assessment of immunological and oral clinical conditions in patients undergoing anticancer treatment for leukemia. Int J Pediatr Otorhinolaryngol 77:1088–1093. doi:10.​1016/​j.​ijporl.​2013.​03.​037 PubMedCrossRef
2.
3.
Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Mucositis study section of the multinational association of supportive care in cancer and the international society for oral oncology: updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831PubMedCrossRef
4.
Tolentino Ede S, Centurion BS, Ferreira LH, Souza AP, Damante JH, Rubira-Bullen IR (2011) Oral adverse effects of head and neck radiotherapy: literature review and suggestion of a clinical oral care guideline for irradiated patients. J Appl Oral Sci 19:448–454PubMedCrossRef
5.
Drabko K, Bojarska-Junak A, Kowalczyk JR (2006) Activity of superoxide dismutase and glutathione peroxidase and concentrations of malonyldialdehyde, vitamin E, total antioxidant status and extracellular cytokines concentrations in children with ALL. Med Wieku Rozw 10:861–868
6.
Conti L, Cardone M, Varano B, Puddu P, Belardelli F, Gessani S (2008) Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes. Eur J Immunol 38:750–762PubMedCrossRef
7.
Bien E, Balcerska A (2008) Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers 13:1–26PubMedCrossRef
8.
9.
Shankar AA, Routray S (2012) Trends in salivary diagnostics—a 5-year review of oral oncology (2007–2011). Oral Oncol 48:22–23CrossRef
10.
11.
Nomura Y, Shimada Y, Hanada N, Numabe Y, Kamoi K, Sato T, Gomi K, Arai T, Inagaki K, Fukuda M, Noguchi T, Yoshie H (2012) Salivary biomarkers for predicting the progression of chronic periodontitis. Arch Oral Biol 57:413–420PubMedCrossRef
12.
13.
Byrne ML, O’Brien-Simpson NM, Reynolds EC, Walsh KA, Laughton K, Waloszek JM, Woods MJ, Trinder J, Allen NB (2013) Acute phase protein and cytokine levels in serum and saliva: a comparison of detectable levels and correlations in a depressed and healthy adolescent sample. Brain Behav Immun 34:164–175PubMedCrossRef
14.
Rhodus NL, Ho V, Miller CS, Myers S, Ondrey MF (2005) NF-κB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 29(42–45):237
15.
Riis JL, Out D, Dorn LD, Beal SJ, Denson LA, Pabst S, Jaedicke K, Granger DA (2014) Salivary cytokines in healthy adolescent girls: intercorrelations, stability, and associations with serum cytokines, age, and pubertal stage. Dev Psychobiol 56:797–811. doi:10.​1002/​dev.​21149 PubMedCrossRef
16.
Du S, Jia Y, Tang H, Sun Y, Wu W, Sun L, Du J, Geng B, Tang C, Jin H (2014) Immune regulation of hydrogen sulfide in children with acute lymphoblastic leukemia. Chin Med J (Engl) 127:3695–3699
17.
Motawi TM, Zakhary NI, Salman TM, Tadros SA (2012) Serum human leukocyte antigen-G and soluble interleukin 2 receptor levels in acute lymphoblastic leukemic pediatric patients. Asian Pac J Cancer Prev 13:5399–5403PubMedCrossRef
18.
Peragine N, Torelli GF, Mariglia P, Pauselli S, Vitale A, Guarini A, Foà R (2015) Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients. Cancer Immunol Immunother 64:201–211. doi:10.​1007/​s00262-014-1614-z PubMedCrossRef
19.
de Koning BA, Philipsen-Geerling B, Hoijer M, Hählen K, Büller HA, Pieters R (2007) Protection against chemotherapy induced mucositis by TGF-beta(2) in childhood cancer patients: results from a randomized cross-over study. Pediatr Blood Cancer 48:532–539PubMedCrossRef
20.
Harris DJ, Eilers J, Harriman A, Cashavelly BJ, Maxwell C (2008) Putting evidence into practice: evidence-based interventions for the management of oral mucositis. Clin J Oncol Nurs 12:141–152PubMedCrossRef
Metadata
Title
Comparison of saliva interleukin-2 concentration to the condition of gums in children with acute lymphoblastic leukaemia during anti-tumour treatment
Author
Elżbieta Pels
Publication date
01-07-2015
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-015-2750-7

Other articles of this Issue 1/2015

Cancer Chemotherapy and Pharmacology 1/2015 Go to the issue

Original Article

Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro

Original Article

Direct and indirect targeting of MYC to treat acute myeloid leukemia

Original Article

Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers

Original Article

Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy

Original Article

Extension of the Calvert formula to patients with severe renal insufficiency

Original Article

Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits